Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting insulin-like growth factor pathways.

D Yee1

  • 1University of Minnesota Cancer Center, Department of Medicine, Minneapolis, MN 55455, USA. yeexx006@umn.edu

British Journal of Cancer
|March 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Advanced Mobile Laboratory to enable field-based microbial ecology and cell biology across scales.

bioRxiv : the preprint server for biology·2026
Same author

Reduced amygdala habituation to anticipated social rejection in youth with major depressive disorder.

Journal of affective disorders·2026
Same author

Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer.

ESMO open·2025
Same author

ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.

Annals of surgical oncology·2025
Same author

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.

Breast cancer research : BCR·2025
Same author

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same journal

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
See all related articles

Targeting specific molecules, like the type I IGF receptor (IGF-IR), offers promising cancer therapy. Early clinical trials for IGF-IR targeting agents require careful consideration of several key issues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Cancer cell proliferation, survival, and metastasis are often driven by specific molecular pathways.
  • Targeted therapies, such as tamoxifen and trastuzumab in breast cancer, have revolutionized cancer treatment.
  • The type I IGF receptor (IGF-IR) pathway is implicated in various cancers.

Purpose of the Study:

  • To evaluate the type I IGF receptor (IGF-IR) as a potential molecular target for novel cancer therapies.
  • To identify critical issues that need to be addressed in early clinical trials for IGF-IR targeting agents.

Main Methods:

  • Literature review of existing research on IGF-IR in cancer.
  • Analysis of successful targeted therapies to inform future strategies.

Related Experiment Videos

  • Discussion of challenges and considerations for clinical development of IGF-IR inhibitors.

    • Main Results:

    • The IGF-IR pathway plays a significant role in cancer progression and is a validated target.
    • Successful examples of targeted cancer therapies highlight the potential of molecular targeting.
    • Several unresolved issues exist regarding the optimal clinical application of IGF-IR targeting drugs.

    Conclusions:

    • The type I IGF receptor (IGF-IR) represents a promising target for developing new anti-cancer drugs.
    • Careful planning and addressing specific challenges in early clinical trials are crucial for the success of IGF-IR targeting therapies.